Linking clinicians and lab researchers for gene discovery: New publication on the Canadian Rare Disease Models and Mechanisms network

Over 70% of rare diseases are genetic in origin, but our understanding of the biological function of the 19,000 genes in the human genome is still often inadequate to reliably predict whether a defect in a particular gene is likely to cause a specific disease. Now that sequencing technologies that look for defects across the whole genome are becoming commonplace in diagnostics, clinicians attempting to diagnose their patients increasingly encounter the situation where they suspect a certain defect of being causative of the patient’s disease but do not have sufficient biological evidence to provide a certain diagnosis. To get from a “suspicion” about a defect in a gene not previously associated with a disease to biological proof of its effect requires extensive further research in cell and animal models, and this step is frequently one that the original clinician does not have the resources to perform.

The Canadian Rare Diseases Models and Mechanisms (RDMM) network was established to connect clinicians discovering new disease genes with Canadian scientists able to study equivalent genes and pathways in model organisms. It has developed a registry of more than 500 Canadian model organism scientists, representing expertise for over 7,500 human genes. To date, it has made 85 connections between clinicians and the scientists studying their genes of interest and has provided funding for 105 projects. These collaborations help confirm variant pathogenicity and unravel the molecular mechanisms of rare diseases, and also test novel therapies and lead to long-term collaborations. NMD4C collaborates with the RDMM network to ensure that neuromuscular clinicians with a gene of interest have the opportunity to seek scientists with the relevant expertise, as well as enabling NMD scientists to register with the network in order to facilitate future collaborations.

The story of the RDMM to date is nicely summarised in this new article by Boycott et al in the American Journal of Human Genetics:

Boycott KM, Campeau PM, Howley HE, Pavlidis P, Rogic S, Oriel C, Berman JN, Hamilton RM, Hicks GG, Lipshitz HD, Masson JY, Shoubridge EA, Junker A, Leroux MR, McMaster CR, Michaud JL, Turvey SE, Dyment D, Innes AM, van Karnebeek CD, Lehman A, Cohn RD, MacDonald IM, Rachubinski RA, Frosk P, Vandersteen A, Wozniak RW, Pena IA, Wen XY, Lacaze-Masmonteil T, Rankin C, Hieter P.
The Canadian Rare Diseases Models and Mechanisms (RDMM) Network: Connecting Understudied Genes to Model Organisms
Am J Hum Genet. 2020 Feb 6;106(2):143-152. doi: 10.1016/j.ajhg.2020.01.009.
PMID: 32032513

rdmm

Read next...

2024 Dr David Green Award winners from MDC

NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards

We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

NMD4C Launch Canadian Neuromuscular Clinical Trial Network

We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

MDC award $900 000 towards clinical and translational research projects in 2024.

MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants

Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.

SMA outcome measures training graphic

SMA Outcome Measures Training for Physiotherapists and Occupational Therapists

To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.

Congratulations to the 2024 early career award winners. Dr Mireille Khacho and Dr Jean-Philippe Leduc Gaudet.

Congratulations to the 2024 NMD4C Early Career Awards Recipients

We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.